Variants of RANKL protein
US7381792B2 · kind B2 · utility
3Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2003 |
| Grant date | Jun 3, 2008 |
| Priority date | — |
| Expiry date | Feb 6, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor—κB Ligand) variant proteins which may be expressed solubly in E. coli, variants that have substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.